Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight ...

Elon Musk is accomplishing some end-of-the-year goals. The tech billionaire has shared a photo showing off his impressive ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

This comes as Robert F. Kennedy JR. (RFK), who president-elect Donald Trump tapped to lead the Department of Health and Human ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

No one has ever known so much about healthy eating and been less successful at following her own advice.

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk ... for GLP-1 medications varies and the financial impact of these coverage differences. Data Source: ...

The world’s richest man has clashed with incoming Health and Human Services chief Robert F. Kennedy Jr. over the role ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

Obesity is still a challenge for U.S. health. You might think that higher prices of food after the pandemic led to a decline ...

Obesity is still a challenge for U.S. health. You might think that higher prices of food after the pandemic led to a decline ...